<DOC>
	<DOCNO>NCT01298570</DOCNO>
	<brief_summary>This randomize ( 2:1 ) , multi-center , placebo-controlled , phase II efficacy study design compare PFS regorafenib + FOLFIRI chemotherapy ( ARM A ) versus placebo + FOLFIRI ( ARM B ) patient mCRC previously treat FOLFOX regimen .</brief_summary>
	<brief_title>Regorafenib+FOLFIRI Versus Placebo+FOLFIRI 2nd Line Tx Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This randomize ( 2:1 ratio ) , multi-center , placebo-controlled , phase II efficacy study design compare progression-free survival ( PFS ) regorafenib + FOLFIRI ( 5-fluorouracil + leucovorin + irinotecan [ ARM A ] versus placebo + FOLFIRI [ ARM B ] ) patient metastatic colorectal carcinoma ( mCRC ) previously treat FOLFOX ( 5-fluorouracil + leucovorin + oxaliplatin ) regimen . Secondary objective include objective response ( OR ) rate , disease control ( DC ) rate , overall survival ( OS ) . A pharmacokinetic ( PK ) evaluation irinotecan conduct subset patient select site . This trial also incorporate number exploratory analysis design evaluate potential correlation blood tissue biomarkers clinical benefit .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion Criteria Subject must meet inclusion criterion participate study : 1 . Age ≥18 year age ( upper age limit ) 2 . Histological cytological documentation adenocarcinoma colon rectum 3 . Archived , paraffinembedded tissue block ( primary metastatic ) available genomic study require 4 . Metastatic disease amenable surgical resection curative intent 5 . Progression within 6 month follow administration standard regimen [ 2 ] treatment metastatic disease include oxaliplatin follow agent without bevacizumab : 5fluorouracil ( FFU ) without leucovorin levoleucovorin Capecitabine NOTE : In patient receive FOLFOX , oxaliplatin sometimes discontinue due toxicity part maintenance therapy strategy . If patient progress 5FU alone , eligible trial . As example , patient begin FOLFOX CapeOx ( without bevacizumab ) , whose oxaliplatin hold neurotoxicity switch capecitabine monotherapy capecitabine bevacizumab , would consider ONE prior therapy . OR Patients develop metastatic disease within 9 month adjuvant FOLFOX stage II III colon cancer 6 . Measurable disease , define least 1 unidimensionally measurable lesion CT scan define RECIST 1.1 . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 ( see Appendix C ) 8 . Life expectancy least 3 month 9 . Adequate bone marrow , renal , hepatic function , evidence following : absolute neutrophil count ( ANC ) ≥1,500/mm3 platelet ≥100,000/mm3 hemoglobin ≥9.0 g/dL serum creatinine ≤1.5 x upper limit normal ( ULN ) Glomerular filtration rate ( GFR ) ≥30 ml/min/1.73m2 ( see Appendix A ) AST ALT ≤3x ULN ( ≤5.0 × ULN patient liver involvement cancer Bilirubin ≤1.5 X ULN Alkaline phosphatase ≤3 x ULN ( ≤5 x ULN liver involvement cancer ) Amylase lipase ≤1.5 x ULN Spot urine must show 1+ protein urine patient require repeat urine analysis.If repeat urinalysis show 1+ protein , 24hour urine collection require must show total protein excretion &lt; 1000 mg/24 hour INR/PTT ≤1.5 x ULN Patients therapeutically treat agent warfarin heparin allow participate provide prior evidence underlie abnormality coagulation parameter exist . Close monitoring least weekly evaluation perform INR/PTT stable base measurement predose define local standard care . 10 . Women childbearing potential male subject must agree use adequate contraception duration study participation 3 month follow completion therapy . Adequate contraception define medically recommend method ( combination method ) per standard care . 11 . The subject capable understanding comply parameter outline protocol 12 . Signed , IRBapproved write informed consent Exclusion Criteria Any subject meeting follow exclusion criterion baseline ineligible study participation : 1 . Prior treatment regorafenib 2 . More 1 prior chemotherapy regimen mCRC ( see section 3.1.5 ) Previous adjuvant FOLFOX base chemotherapy allow . Prior FOLFIRI single agent irinotecan prohibit . 3 . Known history concomitant malignancy likely affect life expectancy judgment investigator 4 . Pregnant breastfeeding patient . Women childbearing potential must pregnancy test perform maximum 7 day start FOLFIRI treatment , negative result must document start treatment . 5 . History Gilbert 's syndrome 6 . Known DPD deficiency 7 . Pernicious anemia anemia due vitamin B12 deficiency ( due potential masking deficiency leucovorin ) 8 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start Day 1 treatment FOLFIRI 9 . Radiotherapy within 4 week prior first dose FOLFIRI 10 . Active cardiac disease include follow : Congestive heart failure ( New York Heart Association [ NYHA ] ) ≥Class 2 ( see Appendix D ) Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start Day 1 FOLFIRI Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension . ( Systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) 11 . Patients pheochromocytoma 12 . Arterial thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism within 6 month start FOLFIRI 13 . Ongoing infection &gt; Grade 2 accord NCI Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v. 4.0 ) 14 . Known history human immunodeficiency virus ( HIV ) infection 15 . Known history chronic hepatitis B C 16 . Patients seizure disorder require medication 17 . Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week FOLFIRI initiation , clinically stable respect tumor time study entry . Also , patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose stable one month prior follow screen radiographic study ) 18 . History organ allograft 19 . Evidence history bleed diathesis . Any hemorrhage bleeding event &gt; Grade 4 within 4 week start FOLFIRI 20 . Nonhealing wound , ulcer , bone fracture 21 . Renal failure require hemo peritoneal dialysis 22 . Dehydration accord NCICTC v 4.0 Grade &gt; 1 23 . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result 24 . Known hypersensitivity study drug , study drug class , excipients formulation 25 . Interstitial lung disease ongoing sign symptoms time inform consent 26 . Inability swallow oral medication 27 . Any malabsorption condition 28 . Unresolved toxicity high CTCAE v. 4.0 Grade 1 attribute prior therapy/procedure exclude alopecia oxaliplatininduced neurotoxicity ( must ≤Grade 2 ) 29 . Patients unable unwilling discontinue ( substitute necessary ) use prohibit drug least 30 day prior Day 1 FOLFIRI initiation ( see Appendix B list prohibit drug ) 30 . Unwilling provide consent genetic study tumor , whole blood , plasma specimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>K-RAS mutation</keyword>
	<keyword>BRAF mutation</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>BAY 73-4506</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5-FU</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Phase II</keyword>
	<keyword>Multi-Center</keyword>
	<keyword>Randomized</keyword>
	<keyword>Lineberger</keyword>
	<keyword>North Carolina Cancer Hospital</keyword>
	<keyword>UNC</keyword>
</DOC>